Elypta is developing an exceptionally sensitive liquid biopsy platform for early detection and monitoring of cancer. Elypta’s assay kit enables measurement of a novel panel of biomarkers and algorithms in Elypta’s cloud-based softwareprovide clinically useful scores. The first application on the market will be a blood test for early detection of recurring or progressing cancer, starting withrenal cell carcinoma. The test will increase the chance of curative treatment for patients.